Drug intelligence / Profile preview

telmisartan + clonidine

Development stage
Phase 4
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Oral
01

Overview

Telmisartan + clonidine is a fixed-dose combination of two antihypertensive agents: **telmisartan**, an angiotensin II receptor blocker (ARB), and **clonidine**, an alpha-2 adrenergic receptor agonist. Telmisartan blocks the angiotensin II type 1 (AT1) receptor, thereby inhibiting the renin-angiotensin-aldosterone system, resulting in vasodilation and reduced blood pressure. Clonidine acts centrally at the alpha-2 adrenergic receptors in the brainstem to decrease sympathetic outflow, leading to reduced peripheral vascular resistance and blood pressure. This combination is used for the management of hypertension, particularly in cases where monotherapy is inadequate. The combination aims to achieve additive or synergistic blood pressure reduction due to their complementary mechanisms of action. While combination products containing telmisartan and other antihypertensive agents (such as amlodipine or hydrochlorothiazide) are marketed, the specific combination of telmisartan + clonidine is less common and may be found in certain markets or in custom compounded formulations.

02

Targets

ADRA2A (α2A)AGTR1 (Angiotensin II Type-1 receptor)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on telmisartan + clonidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on telmisartan + clonidine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call